Clinical Trial Update: Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

The update describes a Phase 1 trial investigating CD83 CAR T cells for relapsed or refractory acute myeloid leukemia, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD83 CAR T Cells

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING